5-Amino-1MQ vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Eloralintide has stronger research evidence (Phase 2 Clinical Trial) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | 5-Amino-1MQ | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 50-75 mg daily Once daily, morning | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection or oral | Oral tablet |
| Typical Duration | 4-6 weeks (cycling recommended) | 36 weeks in Phase 2 trials |
| Best Time to Take | Morning, fasted | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: 5-Amino-1MQ vs Eloralintide
What is the difference between 5-Amino-1MQ and Eloralintide?
5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, 5-Amino-1MQ or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. 5-Amino-1MQ is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can 5-Amino-1MQ and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using 5-Amino-1MQ and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.